United States

Innovus Pharmaceuticals Inc (INNV.PK)

INNV.PK on OTC Markets Group

24 Mar 2017
Change (% chg)

$0.00 (+4.08%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Innovus Pharma sees FY 2016 revenue $5 million
Friday, 18 Nov 2016 06:00am EST 

Innovus Pharmaceuticals Inc : Innovus Pharma continues to execute with record Q3 '16 revenue -- SECfilings.com . Q3 revenue rose 947 percent to $1.9 million . Sees FY 2016 revenue $5.0 million .Sees FY 2017 revenue $15 million.  Full Article

Innovus Pharmaceuticals Q3 loss per share $0.04
Thursday, 10 Nov 2016 04:01pm EST 

Innovus Pharmaceuticals Inc : Innovus pharma reports record quarterly revenues for the third quarter of 2016, increasing 947% to $1.9 million, and record nine months ended september 2016 revenues, increasing 463% to $3.1 million . Q3 loss per share $0.04 . Sees fy 2016 revenue $5.0 million .Q3 revenue rose 947 percent to $1.9 million.  Full Article

Innovus Pharma Q1 loss per share $0.02
Friday, 20 May 2016 06:10am EDT 

Innovus Pharmaceuticals Inc : Innovus Pharma CEO provides shareholder update and conference call .Q1 loss per share $0.02.  Full Article

Innovus Pharmaceuticals Inc enters into license agreement with Elis Pharmaceuticals - Form 8k
Tuesday, 7 Jul 2015 06:05am EDT 

Innovus Pharmaceuticals Inc:Announces that it had entered into an exclusive license agreement with Elis Pharmaceuticals, an emirates company.Says under this Innovus Pharma granted to Elis an exclusive license to market and sell Innovus Pharma’s topical product.Zestra for female sexual dysfunction, treatment for premature ejaculation EjectDelay, its product Sensum+ to increase penile sensitivity, Vesele to increase sexual and cognitive health and Zestra Glide, its high viscosity water-based lubricant in Turkey and select African and gulf countries.Says under the agreement, Innovus Pharma is eligible to receive up to $35.5 million dollars in sales milestone payments plus an agreed-upon transfer price.  Full Article

Innovus Pharmaceuticals Inc announces departure of chief financial officer - Form 8k
Wednesday, 24 Jun 2015 05:16pm EDT 

Innovus Pharmaceuticals Inc:Announces that Lynnette Dillen, executive vice president and chief financial officer of the company has decided to leave the company for another opportunity in the biotechnology industry.Says Dillen is expected to remain in her current role at Innovus effective no later than July 16.  Full Article

More From Around the Web

BRIEF-Innovus Pharma announces cash redemption of outstanding convertible notes

* Innovus Pharmaceuticals announces the cash redemption of all outstanding convertible notes Source text for Eikon: Further company coverage: